Mie Study of Clopidogrel Low Responder in Atherothrombotic Disease Patients with/without Diabetes

Mie Study of Clopidogrel Low Responder in Atherothrombotic Disease Patients with/without Diabetes - Mie Study of Clopidogrel Low Responder in Atherothrombotic Disease Patients with/without Diabetes (McLORDD Study)

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000001574

Enrollment

250

Registered

2008-12-15

Start date

2008-11-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atherothrombotic disease

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Stable atherothrombotic patients (coronary disease and cerebral infarction without embolization from the heart) before taking clopidgrel or taking clopidgrel more than 14days or taking cilostazol. 2) Patients have the following laboratory data Ht 33-52% Platelet 119000-50200/uL Triglyceride 41-824 mg/dL T-Cholesterol 98-316 mg/dL Fibrinogen 171-599 mg/dL 3) Written informed consent from the patient

Exclusion criteria

Exclusion criteria: 1) Patients before operation 2) Cerebral infraction without embolization from the heart 3) Taking following drugs, warfarin, thrombolytic agents, heparin, etc. anti-platelet drugs except aspirin, clopidogrel or cilostazol (e.g., sarpogrelate, diryridamole, EPA, etc.) 4) Not eligible determind by the responding physician

Design outcomes

Primary

Measure	Time frame
To develop the monitoring techniques of poor-responder for clopidgrel	—

Secondary

Measure	Time frame
Relationship of SNIP of CYP2C19 Relationship of DM	—

Countries

Japan

Contacts

Public ContactYuki Nishimura

Mie university hospital Clinical research support center

ynishimura@clin.medic.mie-u.ac.jp059-231-5278

Outcome results